Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
A real-world study of the association between nivolumab exposure and efficacy in patients with metastatic melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower healing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results